Prospective Stratification of Infectious Risks in Multiple Sclerosis (NCT04036097) | Clinical Trial Compass
CompletedNot Applicable
Prospective Stratification of Infectious Risks in Multiple Sclerosis
Switzerland298 participantsStarted 2019-04-10
Plain-language summary
This monocentric study is to identify factors that increase the susceptibility for infections and establish a questionnaire-based infection score that allows a prospective stratification for infectious risks in patients with multiple sclerosis (MS) (InRIMS-Study). The study will utilize a validated, MS-adapted questionnaire and infection diary from the Airway Infection Susceptibility (AWIS) study in a regularly followed, prospective cohort of MS patients. It is a nested project of the prospective observational Swiss MS Cohort (SMSC) and SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation) studies.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Signed informed consent form (ICF) for the InRIMS-study and Swiss MS Cohort (SMSC) and/or Serially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT) study
Exclusion Criteria:
* Not able to sufficiently understand the patient information and questionnaire (German language)
* MS Patients with long-term antibiotic prophylaxis
* MS Patients with known primary immunodeficiency, under chemotherapy due to any malignancy or HIV infection.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial tracked infection risk in people with multiple sclerosis using something called an AWIS RTI score and an infection diary — what do these tools actually measure, and could my own infection history tell us something useful about my MS treatment risks?
2Since this study has already been completed, have any results been published or shared that my care team could look at to help understand how my specific MS treatments might affect my chances of getting infections?
3The trial was focused on 'stratifying' or sorting patients by infection risk — does that mean there are recognized categories of risk among MS patients, and where might I fall based on my current health and any medications I'm on?
4This wasn't a treatment trial, it was observational — so how does the kind of data it collected about infection patterns actually influence the real-world decisions doctors make about which MS therapies to recommend?
5Some MS disease-modifying therapies are known to affect the immune system significantly — based on what studies like this one have found, should we be doing any regular monitoring or preventive steps to reduce my infection risk before or during treatment?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.